NCT02067858终止不适用
An Outcome Analysis for Stereotactic Body Radiation Therapy (SBRT) Treatment of Non-Small Lung Cancer Patients Using 4D PET/CT With Real-Time Position Management (RPM™) System and a Concomitant Evaluation of the Impact and Performance Characteristics of the Immobilization System
Steven Burton1 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2011年4月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Assess Clinical Response Rate and Local Control Following SBRT Treatment of Patients With Early Stage NSCLC
研究概览
简要总结
The goals of this clinical research are to evaluate the outcomes and tumor response for early stage non-small lung cancer (NSCLC) patients undergoing Stereotactic Body Radiation Therapy (SBRT) using four dimensional (4D) Positron Emission Tomography (PET) and Computed Tomography (CT), Cone-Beam Computed Tomography (CBCT), Real-Time Position Management (RPM™) and body immobilization system (see figure 1). Specifically, the effect of image-guided SBRT treatment on clinical tumor response rate, local control and progression-free survival will be studied. This study will examine target volumes and relevant margins determined by an assessment using 4D PET and repeated 4D CT. These data will allow us to evaluate and determine the impact of the body immobilization system on the planning target volume (PTV) margins, patient's breathing pattern, target motion, and inter-treatment targets shifts.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient must be over the age of 18 years. Histologic confirmation of primary NSCLC of the lung tumor must be complete prior to SBRT treatment.
- •The following stages of NSCLC patients would be eligible for the study:
- •T1 N0 M0 T2 N0 M0 (Size ≤ 5 cm)
- •T3 N0 M0 (Chest wall invasion only, Size ≤ 5 cm)
- •Staging Tumor size and characteristics: they will be determined by PET-CT scan
- •Nodal disease:
- •Patients with chest CT scan demonstrating hilar or mediastinal nodes <1cm and/or PET negative would be considered N0 disease.
- •Patients who have hilar or mediastinal nodes > 1 cm and PET scan negative may be considered N0 disease.
- •If PET scan demonstrates suspicious uptake or abnormal uptake, these patients would be eligible, if a directed biopsy (by mediastinoscopy, Chamberlein procedure or other modalities such as trans-bronchial biopsy, CT guided biopsy) is negative.
- •Metastases:
- •Evaluated by PET-CT scanning and biopsy as indicated
- •The patient must have an ECOG/Zubrod performance status of 0, 1, or
- •In order to be considered medically-inoperable, the patient must meet at least one major criterion or meet a minimum of 2 minor criteria as described below.
- •MAJOR CRITERIA:
- •FEV1 < 50% or predicted postoperative FEV1 < 40% DLCO < 50% or predicted postoperative DLCO < 40% Exercise induced maximal exercise oxygen consumption (MVO2)<15 ml/kg/min Thoracic surgery consultation should be obtained from a Board Certified Thoracic surgeon who in collaboration with a radiation oncologist should determine if the patient is medically operable This criterion would be mandatory
- •MINOR CRITERIA:
- •Age > 80 Pulmonary hypertension (defined as a pulmonary artery systolic pressure greater than 40mm Hg) Oxygen requirement (using the Medicare criteria for home oxygen requirements [i.e., room air oxygen saturation of 88% or less]) Congestive heart failure (any three of the following must be documented: dyspnea, peripheral edema, chest x-ray with interstitial edema or cardiomegaly, rales, or congestion) Poor left ventricular function (defined as an ejection fraction of 40% or less) Severe cerebral (with CVA or recent TIA) or severe peripheral vascular disease Diabetes Mellitus with severe organ damage such as End-Stage Renal Disease (ESRD), Blindness, Vascular disease.
- •CBC, Diff and platelets, Comprehensive metabolic panel within 28 days of registration meeting the following criteria
- •leukocytes >3,000/mcL absolute neutrophil count >1,500/mcL hemoglobin >9 g/dL (hemoglobin may be supported by transfusion or erythropoietin or other approved hematopoietic growth factors) platelets >100,000/mcL total bilirubin <1.5x institutional upper limit of normal creatinine within normal institutional limits OR creatinine clearance >60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.
- •Females of child-bearing age must be using a reliable form of birth control. The patient must provide a signed and dated written informed consent PRIOR to registration and prior to undergoing any study-related procedures.
- •The patient must provide written authorization to allow for the use and disclosure of their protected Health information.
- •Conditions for Patient Ineligibility The patient's weight exceeds the tolerances of the institution's imaging and treatment platform/couch.
- •The patient has received thoracic radiation therapy in the same region as the current SBRT planned treatment area. The patient has completed chemotherapy within 30 days of treatment. T2: Tumor size > 5 cm, T3 tumors (except T3 by virtue of chest wall invasion and ≤ 5cm), T4 tumors. Presence of N1, N2 or N3 disease per previously described criteria would also be excluded.
- •Pancoast tumors would be excluded. Current distant metastatic disease (M1) (preferably biopsy proven). The patient is a female with child-bearing potential who refuses to obtain a serum pregnancy test prior to the initiation of treatment.
- •The patient is pregnant or a female who is nursing an infant. The patient is planning on undergoing systemic therapy within 2 weeks after the last fraction of radiation The patient has an active systemic or pulmonary infection.
排除标准
- 未提供
研究组 & 干预措施
Stereotactic Radiosurgery
Other
3 fractions x 20 Gy 4 fractions x 12 Gy
Lesion dependent
干预措施: Stereotactic Radiosurgery (Radiation)
结局指标
主要结局
Assess Clinical Response Rate and Local Control Following SBRT Treatment of Patients With Early Stage NSCLC
时间窗: 2 years
The Number of Patients that completed SBRT
次要结局
- Assess Progression-free Survival(2 years)
研究者
Steven Burton
Associate Professor
University of Pittsburgh
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Evaluation of Stereotactic Body Radiotherapy as a Bridge Therapy for Hepatocellular Carcinoma Patients Enlisted for Liver TransplantationHepatocellular CarcinomaNCT06218420Assistance Publique - Hôpitaux de Paris139
已完成
1 期
Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine CancerRecurrent Endometrial Serous AdenocarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRecurrent Fallopian Tube CarcinomaNCT03325634University of Colorado, Denver15
终止
1 期
Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian CancerRecurrent Ovarian Epithelial CancerRecurrent Ovarian Germ Cell TumorMalignant Tumor of PeritoneumStage IV Ovarian Epithelial CancerStage IV Ovarian Germ Cell TumorNCT01494012Stanford University1
终止
1 期
To Evaluate Stereotactic Body Radiotherapy for Treatment of Primary Renal Cell Carcinoma TumorsPrimary TumorRenal Cell CarcinomaNCT02410174Beth Israel Medical Center3
已完成
1 期
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate CancerProstate AdenocarcinomaStage IV Non-Small Cell Lung CancerStage IV Breast CancerStage IV Prostate CancerMale Breast CarcinomaRecurrent Breast CarcinomaRecurrent Non-Small Cell Lung CarcinomaRecurrent Prostate CarcinomaNCT02206334NRG Oncology42